BridgeBio Pharma, Inc. (BBIO)
$63.30-3.73%Close
SELLRECOVERY · day 9
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $12.4B
- Beta
- 0.97
- P/E (TTM)
- -17.68
- Short % float
- 11.63%
- Days to cover
- 5.8
- SI change
- -8.7%
- 1W
- -5.47%
- 1M
- -12.54%
- vs SPY 1W
- -5.33%
- vs SPY 1M
- -15.05%
Industry peers
FMP comparable companies · ranked by market cap
- ALNYSELLAlnylam Pharmaceuticals, Inc.$30.0BRECOVERYQ 28$224.41-1.41%
- ASNDSELLAscendis Pharma A/S$14.2BRECOVERYQ 35$228.41-1.67%
- BMRNSELLBioMarin Pharmaceutical Inc.$10.7BBEARQ 12$55.20-1.82%
- IONSSELLIonis Pharmaceuticals, Inc.$7.3BCRISISQ 8$44.16-2.95%
- PTCTSELLPTC Therapeutics, Inc.$5.3BCRISISQ 18$63.23-4.77%
- SRRKSELLScholar Rock Holding Corporation$5.1BCRISISQ 22$42.20-3.39%
- TVTXSELLTravere Therapeutics, Inc.$5.0BCRISISQ 33$53.44-0.42%
- DNLISELLDenali Therapeutics Inc.$3.0BCRISISQ 8$19.16-2.90%
- RAREBUYUltragenyx Pharmaceutical Inc.$1.5BRECOVERYQ -6$14.89-2.48%
- MAZEBUYMaze Therapeutics, Inc.$1.5BRECOVERYQ 36$26.25-3.75%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on BBIO?
- LOPJLB’s latest quantitative signal on BridgeBio Pharma, Inc. (BBIO) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is BBIO in?
- BridgeBio Pharma, Inc. (BBIO) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does BridgeBio Pharma, Inc. (BBIO) do?
- BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG…